首页> 外文期刊>Manufacturing and service operations management >Optimal Vascular Access Choice for Patients on Hemodialysis
【24h】

Optimal Vascular Access Choice for Patients on Hemodialysis

机译:血液透析患者的最佳血管通路选择

获取原文
获取原文并翻译 | 示例
       

摘要

Which vascular access to use is considered one of the most important questions in the care of patients on hemodialysis (HD). An arteriovenous fistula (AVF) is often considered the gold standard for delivering HD due to better patient survival, higher quality of life, and fewer complications. However, AVFs have some limitations: they require surgery, it takes approximately three months to know whether the surgery was successful, and a majority of these surgeries end in failure. Conversely, another common vascular access, the central venous catheter, can be inserted via a simple procedure and used immediately after placement. In this research, we address the question of whether and when to perform AVF surgery on incident and established HD patients, with the aim of finding individualized policies that maximize a patient's probability of survival and remaining quality-adjusted life expectancy. Using a continuous-time dynamic programming model and under certain data-driven assumptions, we establish structural properties of the optimal policy for each objective. We provide further insights for policy makers through our numerical experiments.
机译:使用哪种血管通路被认为是血液透析(HD)患者护理中最重要的问题之一。动静脉瘘(AVF)通常被认为是提供HD的黄金标准,原因是患者生存期更长,生活质量更高,并发症更少。但是,AVF有一些局限性:它们需要进行手术,大约需要三个月才能知道手术是否成功,并且这些手术中的大多数以失败告终。相反,另一种常见的血管通路,即中心静脉导管,可通过简单的程序插入并在放置后立即使用。在这项研究中,我们解决了是否以及何时对事件和既定的HD患者进行AVF手术的问题,目的是找到能够最大程度地提高患者的生存可能性和质量调整后的预期寿命的个性化策略。使用连续时间动态规划模型并在某些数据驱动的假设下,我们为每个目标建立了最优策略的结构属性。我们通过数值实验为决策者提供进一步的见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号